OncoMatch/Clinical Trials/NCT03629171
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
Is NCT03629171 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax for recurrent acute myeloid leukemia.
Treatment: Liposome-encapsulated Daunorubicin-Cytarabine · Venetoclax — This phase II trial studies how well liposome-encapsulated daunorubicin-cytarabine and venetoclax work in treating participants with acute myeloid leukemia that has come back (relapsed), does not respond to treatment (refractory), or has not been treated (untreated). Drugs used in chemotherapy, such as liposome-encapsulated daunorubicin-cytarabine and venetoclax, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Acute Myeloid Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: CPX-351 (CPX-351)
Prior treatment with CPX-351
Cannot have received: BCL2 inhibitor (venetoclax)
Exception: Patients with prior treatment with venetoclax will be allowed in patients with relapsed/refractory (R/R) disease including those in the lead-in phase as well as those in cohort A
Prior treatment with venetoclax. Patients with prior treatment with venetoclax will be allowed in patients with relapsed/refractory (R/R) disease including those in the lead-in phase as well as those in cohort A
Lab requirements
Kidney function
Creatinine <= 1.5 x ULN
Liver function
Bilirubin <= 2 mg/dL; AST and/or ALT <= 3 x ULN or < 5 x ULN if related to leukemic involvement
Cardiac function
Known cardiac ejection fraction of >= 45% within the past 3 months
Bilirubin <= 2 mg/dL; AST and/or ALT <= 3 x ULN or < 5 x ULN if related to leukemic involvement; Creatinine <= 1.5 x ULN; Known cardiac ejection fraction of >= 45% within the past 3 months
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- M D Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT03629171 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior CPX-351, BCL2 inhibitor disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 69 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages